Characterizing T-cell epitopes of pathogens that cause localized infections such as human papillomavirus is a challenge because of limited number of T cells in circulation. A method is described in which rare T cells were isolated and were characterized starting with a very small number of cells.
A protocol has been developed to overcome the difficulties of isolating and characterizing rare T cells specific for pathogens, such as human papillomavirus (HPV), that cause localized infections. The steps involved are identifying region(s) of HPV proteins that contain T-cell epitope(s) from a subject, selecting for the peptide-specific T cells based on interferon-γ (IFN-γ) secretion, and growing and characterizing the T-cell clones (Fig. 1). Subject 1 was a patient who was recently diagnosed with a high-grade squamous intraepithelial lesion by biopsy and underwent loop electrical excision procedure for treatment on the day the T cells were collected1. A region within the human papillomavirus type 16 (HPV 16) E6 and E7 proteins which contained a T-cell epitope was identified using an IFN- g enzyme-linked immunospot (ELISPOT) assay performed with overlapping synthetic peptides (Fig. 2). The data from this assay were used not only to identify a region containing a T-cell epitope, but also to estimate the number of epitope specific T cells and to isolate them on the basis of IFN- γ secretion using commercially available magnetic beads (CD8 T-cell isolation kit, Miltenyi Biotec, Auburn CA). The selected IFN-γ secreting T cells were diluted and grown singly in the presence of an irradiated feeder cell mixture in order to support the growth of a single T-cell per well. These T-cell clones were screened using an IFN- γ ELISPOT assay in the presence of peptides covering the identified region and autologous Epstein-Barr virus transformed B-lymphoblastoid cells (LCLs, obtained how described by Walls and Crawford)2 in order to minimize the number of T-cell clone cells needed. Instead of using 1 x 105 cells per well typically used in ELISPOT assays1,3, 1,000 T-cell clone cells in the presence of 1 x 105 autologous LCLs were used, dramatically reducing the number of T-cell clone cells needed. The autologous LCLs served not only to present peptide antigens to the T-cell clone cells, but also to keep a high cell density in the wells allowing the epitope-specific T-cell clone cells to secrete IFN-γ. This assures successful performance of IFN-γ ELISPOT assay. Similarly, IFN- γ ELISPOT assays were utilized to characterize the minimal and optimal amino acid sequence of the CD8 T-cell epitope (HPV 16 E6 52-61 FAFRDLCIVY) and its HLA class I restriction element (B58). The IFN- γ ELISPOT assay was also performed using autologous LCLs infected with vaccinia virus expressing HPV 16 E6 or E7 protein. The result demonstrated that the E6 T-cell epitope was endogenously processed. The cross-recognition of homologous T-cell epitope of other high-risk HPV types was shown. This method can also be used to describe CD4 T-cell epitopes4.
Traditionally, immunologists attempted to characterize novel T-cell epitopes by stimulating the T-cells of interest in vitro, and performing a limiting dilution experiment to isolate the epitope-specific T-cell clones. Then the T-cell clones were characterized using a chromium release assay 8,9. However, many attempts were unsuccessful because the frequencies of the T-cells may have been too low to be isolated or because not enough T-cell clone cells were available to complete the characterization. Th…
The authors have nothing to disclose.
This study was supported by an American Cancer Society Scholars Award (RSG-06-180-01-MBC) and NIH grants (R01 CA143130 and UL1RR029884).
Name of reagent | Company | Catalog Number | Comments |
CD8 T cell isolation kit | Miltenyi | 130-094-156 | |
Phytohemagglutinin | Remel | R-30852801 | 2mg/vial |
Yssel’s medium | Gemini Bio-Products | 400-102 | 1% pooled human serum |
96-well round bottom plate | BD Falcon | 08-772-17 | |
Recombinant human IL-2 | R&D | 202-IL-050 | 50μg |
24-well plate | Corning Costar | 07-200-84 | |
Phosphate-buffered saline | Cellgro | MT-21-031-CV | |
Primary anti-IFN-γ monoclonal antibody (D1K) | Mabtech | 3420-3-1000 | |
Biotin-conjugated anti-IFN-γ monoclonal antibody (7B-6) | Mabtech | 3420-6-1000 | |
Multiscreen HA ELISPOT plate | Millipore | MAHA S45 10 | |
Dimethyl Sulphoxide | Sigma | D2650 | 100 ml bottle |
Pooled Serum, human | Atlanta Biologicals | S40510H | Heat inactivate |
RPMI 1640 | Cellgro | MT-10-040-CV | |
Tween-20 | Sigma | P2287-100ml | |
Vectastain Elite ABC Kit | Vector Labs | NC9313719 | |
Stable diaminobenzidine | Open Biosystems | MBI 1241 | |
AID EliSpot Reader Classic | Autoimmun Diagnostika GmbH | ELR06 |